BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
disorders, today announced that Sanj K. Patel, President and Chief
Executive Officer, will present at the Jefferies 2012 Global Healthcare
Conference in London, England on Wednesday, November 14th,
2012, at 10:00 a.m. GMT (5:00 a.m. EST). In addition, the company will
host one-on-one meetings at the Leerink Swann Management Access Day on
November 20, 2012 in Boston, MA.
The Jefferies conference presentation will be webcast live and may be
accessed from the “Webcasts & Presentations” section of the Investor
Relations tab on the home page of Synageva’s website at www.synageva.com.
About Synageva’s Lead Program
alfa is a recombinant form of the human Lysosomal Acid Lipase (LAL)
enzyme under development by Synageva as an enzyme replacement therapy
for LAL Deficiency, a lysosomal storage disorder (LSD). Synageva
currently evaluates sebelipase alfa in global clinical trials.
Sebelipase alfa has been granted orphan designations by the U.S. Food
and Drug Administration (“FDA”), the European Medicines Agency, and the
Japanese Ministry of Health, Labour and Welfare. Additionally,
sebelipase alfa received “fast track” designation by the FDA.
About LAL Deficiency
Acid Lipase Deficiency is a rare, autosomal recessive LSD that is
caused by a marked decrease in LAL enzyme activity. Late onset LAL
Deficiency, sometimes called Cholesteryl Ester Storage Disease (CESD),
affects both children and adults. In these patients, the buildup of
fatty material in the liver, spleen and blood vessel walls leads to
complications resulting in significant morbidity and mortality. Early
onset LAL Deficiency, sometimes called Wolman disease, affects infants
and is characterized by severe malabsorption, growth failure, and
hepatic failure and is usually fatal within the first year of life.
About Synageva BioPharma Corp.
Synageva is a clinical stage biopharmaceutical company focused on the
discovery, development, and commercialization of therapeutic products
for patients with life-threatening rare diseases and unmet medical need.
Synageva has several protein therapeutics in its pipeline. The company
has assembled a team with a proven record of bringing orphan therapies
Further information regarding Synageva BioPharma Corp. is available at www.synageva.com.
This news release contains “forward-looking statements” under the
provisions of the Private Securities Litigation Reform Act of 1995. Such
statements can be identified by introductory words such as “expects,”
“plans,” “intends,” “believes,” “will,” “estimates,” “forecasts,”
“projects,” or words of similar meaning, and by the fact that they do
not relate strictly to historical or current facts. Many factors may
cause actual results to differ materially from forward-looking
statements, including inaccurate assumptions and a broad variety of
risks and uncertainties, some of which are known, including those
identified under the heading “Risk Factors” in the Company’s Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission
(the “SEC”) on November 6, 2012 and other filings Synageva periodically
makes with the SEC, and others of which are not. Synageva cannot be sure
when or if it will be permitted by regulatory agencies to undertake
additional clinical trials or to commence any particular phase of
clinical trials or how quickly patient enrollment in clinical trials
will occur. In addition, early clinical results are not necessary
predictive of results that may be achieved from subsequent clinical
trials. Because of this, statements regarding the expected timing of
clinical trials or ultimate regulatory approval cannot be regarded as
actual predictions of when Synageva will obtain regulatory approval for
any phase of clinical trials or when it will obtain ultimate regulatory
approval by a particular regulatory agency or when any of its drug
product candidates might be commercialized. No forward-looking statement
is a guarantee of future results or events, and investors should avoid
placing undue reliance on such statements. Synageva undertakes no
obligation to update any forward-looking statements, whether as a result
of new information, future events or otherwise.
“Dedicated to Rare Diseases®” is a registered trademark and “Synageva
BioPharma™” is a trademark of Synageva BioPharma Corp.